July 16th 2024
Laura W. Goff, MD, MSCI, MMHC, discusses the onslaught of treatment sequencing available in gastrointestinal cancer.
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
FDA Grants Priority Review to BLA for Retifanlimab as Possible Treatment for SCAC
January 22nd 2021The BLA submission is based on data observed in the phase 2 POD1UM-202 trial of retifanlimab in previously treated patients with locally advanced or metastatic squamous cell carcinoma of the anal canal who had progressed on, or were intolerant of, standard platinum-based chemotherapy.
FDA Approves Fam-Trastuzumab Deruxtecan-nxki for HER2+ Gastric or GEJ Adenocarcinoma
January 15th 2021The approval was based on results from the phase 2 DESTINY-Gastric01 trial which evaluated patients with HER2-positive locally advanced or metastatic gastric or GEJ adenocarcinoma who had progressed on at least 2 prior regimens.
Novel AI Tool Helps Patients to Find, Understand Clinical Trials
January 15th 2021Cancertrialsearch.com helped to match patients with gastrointestinal cancers to clinical trials using 7 different criteria, possibly paving the way for patients to find, understand, and enroll in oncology clinical trials.
Study Suggests Need to Develop Therapeutic Modalities to Target Early-Onset Appendiceal Cancer
December 26th 2020This study indicated that appendiceal cancer diagnosed among younger individuals harbors a distinct genomic landscape, as compared with appendiceal cancer diagnosed among older individuals.
FDA Grants Priority Review to Pembrolizumab Plus Chemo for Advanced Esophageal or GEJ Cancer
December 17th 2020The FDA granted priority review to a new supplemental biologics license application for pembrolizumab (Keytruda) in combination with chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic esophageal and gastroesophageal junction cancer.
UDCA May Be Associated with Reduction of Biliary Tract Cancer, Need for Liver Transplantation
November 24th 2020Data from a Japanese cohort of patients with primary sclerosing cholangitis suggested ursodeoxycholic acid (UDCA) was significantly associated with reduced mortality or need for liver transplantation and was also likely to be associated with a reduction of biliary tract cancer.
FDA Grants Priority Review to Trastuzumab Deruxtecan for HER2+ Metastatic Gastric, GEJ Cancer
October 28th 2020The FDA granted priority review to the supplemental biologics license application for trastuzumab deruxtecan (Enhertu) for the treatment of patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma.
Phase 3 ORIENT-32 Trial Shows Promise for First-Line Treatment Combo in HCC
September 28th 2020The study is evaluating the efficacy and safety of sintilimab injection in combination with bevacizumab biosimilar injection compared to sorafenib in the first-line treatment of patients with advanced hepatocellular carcinoma.
Compared to Standard of Care, HAIC Demonstrates Better Safety and Efficacy in Unresectable HCC
September 24th 2020Hepatic arterial infusion chemotherapy with oxaliplatin, fluorouracil, and leucovorin significantly improved overall survival compared with transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.
Adding Nivolumab to Chemo Improves PFS, Elicits Higher ORR in Gastric/GEJ Cancers
September 24th 2020The addition of nivolumab (Opdivo) to chemotherapy resulted in a statistically significant improvement in PFS and evoked higher ORRs in patients with previously untreated advanced or recurrent gastric and gastroesophageal junction cancer.
Phase 3 CheckMate-649 Study Sees Promising Survival Benefit with Frontline Nivolumab, Chemo Combo
September 22nd 2020The combination of nivolumab (Opdivo) and chemotherapy led to a statistically significant survival benefit among previously untreated patients with PD-L1–positive advanced gastric cancer, gastroesophageal junction cancer, and esophageal adenocarcinoma.
Phase 3 KEYNOTE-590 Trial Finds Pembrolizumab, Chemo Combo Effective for Advanced Esophageal Cancer
September 21st 2020Frontline pembrolizumab (Keytruda) plus chemotherapy significantly improved overall survival, progression-free survival, and objective response rates compared with chemotherapy alone in patients with locally advanced unresectable or metastatic esophageal cancer.
Trial Evaluating Nivolumab for Patients with Esophageal Cancer Meets Primary End Point of DFS
August 11th 2020Bristol Myers Squibb’s CheckMate-577 trial, which evaluated nivolumab to treat patients with resected esophageal or gastroesophageal junction cancer, met the primary end point of disease-free survival.
Effect of Lifestyle Factors and Garlic Supplementation on Gastric Cancer Incidence
July 20th 2020This study found that smoking was associated with an increased risk of gastric cancer incidence and mortality, while not drinking was correlated with a stronger beneficial effect of garlic supplementation on gastric cancer prevention.